Boardroom Alpha
Start trial
Boardroom Alpha
TIL · Additional Proxy Materials (DEFA14A) · Filed April 24, 2026

Instil Bio Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 24, 2026
Ticker
TIL
Accession
0001789769-26-000032
Instil Bio Inc on Boardroom AlphaView on SEC EDGAR
Boardroom Alpha · Filing insights

Instil Bio, Inc. filed definitive additional materials; no material governance developments disclosed.

About Instil Bio Inc
Market cap
$55M
1Y TSR
−73.3%
3Y TSR
−10.5%
Board grade
D
Sector
Healthcare
CEO
Bronson Crouch
Last annual meeting: Jun 11, 2026 · View full Instil Bio Inc profile →
Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No.__)
Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
o
Preliminary Proxy Statement
o
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o
Definitive Proxy Statement
x
Definitive Additional Materials
o
Soliciting Material Pursuant to § 240.14a-12
Instil Bio, Inc.
_____________________________
(Name of Registrant as Specified In Its Charter)
_____________________________
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box)
x
No fee required.
o
Fee paid previously with preliminary materials
o
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


























notice1.jpg


notice2.jpg


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

See Meeting ForecastSchedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Instil Bio Inc (TIL)

Continue researching
Reference

Frequently asked questions

When did Instil Bio Inc file this DEFA14A?
Instil Bio Inc (TIL) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 24, 2026. The accession number assigned by EDGAR is 0001789769-26-000032.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Instil Bio, Inc. filed definitive additional materials; no material governance developments disclosed. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Instil Bio Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Instil Bio Inc has filed under CIK 1789769, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer